Avoid common mistakes on your manuscript.
Dear Editor,
With great interest, we read a paper in Breast Cancer Research and Treatment “Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.” by Tian et al [1]. We would like to applaud the authors for finding the anticancer effect of bazedoxifene on breast cancer. However, there are some problems in this paper that need to be addressed.
Authors found that bazedoxifene induced cell apoptosis using the Apo-ONE homogeneous caspase 3/7 assay after the treatment of bazedoxifene (10 μM) for 5 h (Fig. 3). Moreover, Fig. 4 shows that cell viability decreased markedly, which was less than 50% treating with bazedoxifene (10 μM). The same results also can be seen in Fig. 5. However, authors claimed that bazedoxifene (10 μM for 24 h) could inhibit cell invasion significantly without inducing any cell death (Fig. 8). The cell viability was almost 100% after the incubation of bazedoxifene (10 μM) for 24 h (Fig. 8B). These results were contradictory.
Yours sincerely,
Xishan Chen, Ph.D.
The Fourth Affiliated Hospital of Guangxi Medical University
Reference
Tian J, Chen X, Fu S, Zhang R, Pan L, Cao Y, Wu X, Xiao H, Lin HJ, Lo HW, Zhang Y, Lin J (2019) Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Res Treat 175(3):553–566
Funding
This study was not funded by any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
This article does not contain any studies with human participants.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Rights and permissions
About this article
Cite this article
Chen, X., Guo, K. & Lin, J. Letter to the editor regarding the article “Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer”. Breast Cancer Res Treat 185, 883 (2021). https://doi.org/10.1007/s10549-020-05987-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-020-05987-7